MediMabBio has successfully raised KRW 25.6 billion (USD 17 million) in its Series B financing round.
The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.
MediMabBio is advancing next-generation immunotherapies through its proprietary MediLink™ fusion-antibody platform, which combines antibodies with immune-modulating cytokines to deliver enhanced therapeutic efficacy and safety. The lead programme, MFA031, is a fusion protein which restores immune balance in indications such as autoimmune disease and transplant rejection.
The Series B round was led by existing investors including KB Investment, Smilegate Investment, BNH Investment, Hyundai Investment Partners, IM Investment Partners, and Timefolio Asset Management, with participation from eight new institutional investors — Yuanta Investment, Seoul Investment Partners, Sneak Peek Investment, Union Investment Partners, Aon Investment, E&Venture Partners, Dongbang FTL, and HLB Bios Step.
